Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy

Is long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy associated with sustained clinical benefit through 54 months in the open-label extension of ATTRibute-CM?Among 389 participants enrolled in the open-label extension of the ATTRibute-CM randomized clinical trial, early and continuous acoramidis treatment was associated with sustained reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization, with consistent benefit across prespecified demographic and clinical subgroups. Biomarkers, functional capacity, and health status remained stable or improved, and no new long-term safety concerns were identified.These findings support early and continuous acoramidis treatment to achieve long-term disease stabilization in transthyretin amyloid cardiomyopathy.

Corresponding Author: Prem Soman, MD, PhD, Division of Cardiology, University of Pittsburgh Medical Center, 200 Lothrop St, Scaife Hall, A 429, Pittsburgh, PA 15213 (somanp@upmc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.